Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Phillip D. Carrai, president of Kratos Defense & Security Solutions' STC Division, sold 6,500 shares on March 16, 2026, under a pre-arranged 10b5-1 plan for roughly $578,947. The company continues to secure defense contracts and expand programs even as some analysts flag valuation concerns and the firm moves forward with a large equity offering.
Meta Platforms director Robert M. Kimmitt sold 580 Class A shares on March 16, 2026, realizing $366,571 at $632.02 per share. The sale was carried out under a Rule 10b5-1 trading plan adopted August 15, 2025. At the time of reporting, Meta shares were trading at $615.68, roughly 23% below their 52-week high of $796.25, while the company retains a m…
Williams-Sonoma President and CEO Laura Alber sold 19,990 shares on March 16, 2026, for about $3.6 million under a Rule 10b5-1 plan. The transaction was reported on a Form 4; Alber continues to hold a large direct stake and additional indirect holdings. The company posted a fourth-quarter earnings-per-share beat but missed revenue expectations, whi…
MediaAlpha CEO Steven Yi sold 4,000 shares of Class A common stock on March 18, 2026, under a Rule 10b5-1 plan to cover taxes tied to vesting restricted stock units. The company reported Q4 2025 revenue of $291 million, a small miss versus the $295.02 million expected, while maintaining record financial results attributed to strategic initiatives. …
Jamie L. Reynoso, chief executive of Medicare Advantage at Clover Health Investments Corp. (CLOV), sold 5,833 Class A shares on March 18, 2026, for roughly $11,141 under a previously established Rule 10b5-1 trading plan. The firm also reported fourth-quarter 2025 revenue above expectations and disclosed a technical integration with CMS Aligned Netw…
SkyWater Technology CFO Steve Manko sold 91,109 shares on March 16, 2026, realizing roughly $2.5 million in proceeds from transactions priced between $27.54 and $28.10. He also exercised options for 9,708 shares at a $10.14 exercise price. The activity follows a 237% one-year gain for the stock and comes amid IonQ's planned $1.8 billion acquisition…
Rhonda Farnum, Senior Vice President of Communications and Medical Affairs at Theravance Biopharma, sold 31,067 ordinary shares on March 16, 2026, netting roughly $433,637. The trades were carried out under a 10b5-1 plan and leave Farnum with 232,699 shares. The insider activity comes amid the company’s decision to discontinue the ampreloxetine pro…
Prologis director Sarah A. Slusser sold 111 shares of the REIT's common stock across transactions between July 10, 2025 and January 28, 2026, generating about $12,631. The trades occurred at prices between $108.58 and $127.57. Slusser had previously purchased 13 shares on May 14, 2025 at $107.34 and now directly holds 11 Prologis shares. The compan…
Peter Richard Orszag, Lazard Inc.'s chief executive officer and chairman, sold 69,170 Lazard shares on March 17, 2026, realizing roughly $2.8 million. The transactions were made under a Rule 10b5-1 trading plan adopted in March 2025 and are reported to cover estimated taxes and other personal expenses. Separately, Orszag carried out additional shar…
Kratos Defense & Security Solutions director Scott I. Anderson sold 15,000 shares on March 16, 2026, netting $1.33 million in five transactions executed under a 10b5-1 plan adopted September 10, 2025. The sales come amid a near 198% year-over-year share price rise, recent defense contracts and partnerships, and a $1.17 billion equity offering that …
Mark Breitbard, President and CEO of Gap Brand at Gap Inc (NASDAQ:GAP), sold 119,155 shares on March 17, 2026, realizing $2,836,317 via a Rule 10b5-1 program. The filing also records option exercises and a partial disposition tied to those exercises. The transactions come as Gap reports in-line fourth-quarter results, recent plan updates and receiv…
FormFactor Inc CEO Mike Slessor sold 10,227 shares of the company's common stock on March 18, 2026, under a Rule 10b5-1 plan, realizing $973,076. The transactions were executed in three tranches at prices between $93.63 and $95.87. The sale follows the company's fourth-quarter 2025 results, which beat consensus on both EPS and revenue, while the st…
Recursion Pharmaceuticals Chief Financial Officer Ben R Taylor sold 7,956 shares of Class A common stock on March 17, 2026, raising roughly $26,970 at $3.39 per share under a Rule 10b5-1 trading plan. The transaction occurred while the stock traded close to its 52-week low, and follows a net settlement of restricted stock units the previous day. Re…
Limbach Holdings CFO Jayme L. Brooks sold 10,310 shares on March 17, 2026 under a pre-arranged 10b5-1 plan, generating $778,550. The sale comes as the stock trades well below its 52-week high and after a quarter that beat EPS estimates but missed revenue targets. Analysts have kept bullish price targets, citing stronger-than-expected margins and re…
Sumner Crystal, Marqeta's Chief Administrative Officer and Corporate Secretary, reported the sale of 5,055 Class A shares on March 16, 2026, at a weighted average price of $3.9814, yielding $20,125. The filing also shows substantial grant activity in the form of restricted and performance stock units. The transaction comes as the stock trades near …
Jay Sharp, Executive Vice President of Limbach Holdings (NASDAQ: LMB), disposed of 2,000 shares on March 16, 2026, under a pre-existing 10b5-1 plan. The sales, which totaled roughly $160,000, came amid a period of share-price weakness and a quarterly report showing strong earnings per share but a revenue shortfall.
Martha Cummings, a director at Marqeta, sold 2,853 shares on March 16, 2026, for about $11,356. The transaction comes amid a 32% six-month drop in the stock, divergent analyst views and an acceleration in payment volume reported for the fourth quarter of 2025. Marqeta also appointed Patti Kangwankij as CFO effective February 9, 2026.
Global Partners LP Chief Operating Officer Mark Romaine sold 15,611 common units of the partnership between March 16 and March 18, 2026, realizing approximately $740,240. The sales occurred in three tranches at weighted average prices between $47.00 and $47.76. Following the transactions Romaine holds 146,874 units. The stock trades near $47.89, wh…
Indie Semiconductor President Aoki Ichiro sold 100,000 shares of Class A common stock on March 16 and 17, 2026, collecting roughly $256,400. The transactions were carried out under a Rule 10b5-1 trading plan and coincided with a company announcement of a $150 million convertible note private placement and a technology deal with Mahindra & Mahin…
Fady Ibraham Malik, Executive Vice President of Research & Development at Cytokinetics INC (NASDAQ:CYTK), sold 12,033 shares on March 17, 2026, in two transactions executed at $62.15 per share. The filings indicate these were sell-to-cover trades to satisfy tax withholding on vested RSUs. The move comes amid a wave of analyst adjustments and commen…
Cytokinetics President and CEO Robert I. Blum sold 36,601 shares of common stock on March 17, 2026, in two separate transactions at $62.15 per share, generating $2,274,751 in proceeds to satisfy tax-withholding obligations tied to vested restricted stock units. Multiple analysts have recently adjusted price targets higher and commented on clinical …
Unum Group Executive Vice President, Group Benefits, Christopher W. Pyne, sold 4,852 shares on March 16, 2026 under a Rule 10b5-1 plan, generating $351,624. The company recently reported fourth-quarter 2025 results that missed analyst forecasts on both earnings and revenue. Unum's board approved amendments to its bylaws affecting shareholder meetin…
Castellum, Inc. Chief Operating Officer Andrew Merriman purchased 3,000 shares of the company's common stock on March 18, 2026, paying $0.7983 per share for a total of $2,394. The transaction comes as the stock trades near its 52-week low and after the company has eliminated its remaining debt and boosted cash balances. Castellum's subsidiary Speci…
Ardelyx President and CEO Michael Raab sold 41,666 shares of common stock on March 16, 2026, generating roughly $243,329 from trades executed at prices between $5.79 and $5.92. Concurrently, he exercised options to acquire 20,833 shares at $0.99. Following the transactions, Raab directly holds 1,816,448 shares and maintains additional indirect hold…
Gary B Smith, Ciena Corp's president and chief executive officer, sold 2,952 shares on March 16, 2026, for roughly $1.06 million under a Rule 10b5-1 trading plan. The sale came as the stock traded above the reported 52-week high and follows a robust quarter that lifted fiscal 2026 revenue guidance by 4 percentage points and attracted multiple analy…
